- Indometacin sodium
-
- $10.00
-
2021-11-23
- CAS:74252-25-8
- Min. Order: 1Kg/Bag
- Purity: 99%
- Supply Ability: 20 Tons
|
| | INDOMETHACIN SODIUM SALT TRIHYDRATE Basic information |
| Product Name: | INDOMETHACIN SODIUM SALT TRIHYDRATE | | Synonyms: | INDOMETHACIN SODIUM SALT TRIHYDRATE;1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, sodi um salt, trihydrate;1H-Indole-3-aceticacid, 1-(4-chlorobenzoyl)-5-Methoxy-2-Methyl-, sodiuM salt, hydrate (1:1:3);Sodium salt trihydrate;sodium,2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate,trihydrate;Indomethacin sodium hydrate;Indomethacin sodium salt 3-hydrate;Indomethacin sodium trihydrate | | CAS: | 74252-25-8 | | MF: | C34H40ClNO4 | | MW: | 562.146 | | EINECS: | | | Product Categories: | | | Mol File: | 74252-25-8.mol |  |
| | INDOMETHACIN SODIUM SALT TRIHYDRATE Chemical Properties |
| storage temp. | 4°C, protect from light, stored under nitrogen | | solubility | DMSO: 5 mg/mL (11.53 mM) | | form | Solid | | color | Light yellow to yellow | | Water Solubility | Water: 33.33 mg/mL (76.83 mM) | | InChIKey | CFIGYZZVJNJVDQ-LMJOQDENSA-N | | SMILES | C12C=CC(OC)=CC=1C(=C(C)N2C(=O)C1C=CC(Cl)=CC=1)CC(=O)OC/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/C |
| | INDOMETHACIN SODIUM SALT TRIHYDRATE Usage And Synthesis |
| Uses | Anti-inflammatory. | | Brand name | Indocin (Ovation). | | Hazard | A poison by ingestion. | | in vivo | Indomethacin sodium hydrate can be used to create gastric ulcer models. After oral administration, the drug is absorbed rapidly and completely, although there are interindividual and intraindividual variations. The plasma peak concentration of 2-3 μg/mL is typically reached within 1-2 hours. However, coadministration with food reduces and delays the peak concentration without affecting the total absorption. At therapeutic concentrations, 90% of Indomethacin is bound to albumin in the plasma[4].
Induction of gastric ulceration[5][6] Background
Indomethacin can cause gastric ulceration by various mechanisms, including injury through inhibition of prostaglandin (PG) synthesis, reduction in local blood flow, regional irritation, and inhibition of tissue regeneration.
Specific Modeling Methods
Rat: albino Sprague-Dawley male adult (period: 2 weeks)
Administration: 100 mg/kg p.o. single dose
Note
(1) All animals fasted 24 h before drug administration.
(2) Indomethacin were dissolved in saline with 5% NaOH.
Modeling Indicators Gastric tissue macroscopic alterations: Showed prominent mucosal folds and severe erosion, pronounced ulceration and bleeding foci in the gastric mucosa.
Histopathological changes: Showed severe erosion of the mucosa, reaching down to the lamina muscularis; observed hemorrhagic infiltration, edema in the submucosa, and severe hyperemia of the vessels.
Molecular changes: Showed intense Tnf-α expression.
Biochemical changes: Increased MDA, TOS levels, reduced TAS levels, CAT and GPx activities and GSH levels.
Correlated Product(s): Indomethacin sodium hydrate (HY-14397A) Opposite Product(s): Carnosic acid (HY-N0644) | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.01-10 mg/kg | | Administration: | Oral administration; for 3 hours | | Result: | Inhibited the carrageenan-induced rat paw oedema (ED50=2.0mg/kg) and hyperalgesia (ED50=1.5mg/kg) in a dose-dependent manner. |
| Animal Model: | Male C57BL/6J mice[2] | | Dosage: | 10 mg/mL | | Administration: | Oral administration; daily, for 29 days | | Result: | Delayed the onset of tumor growth and the initial growth rate of the footpad tumors. |
|
| | INDOMETHACIN SODIUM SALT TRIHYDRATE Preparation Products And Raw materials |
|